3-Thia-9-azabicyclo[3.3.1]nonan-7-one | 1205682-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Thia-9-azabicyclo[3.3.1]nonan-7-one
• CAS: 1205682-24-1
• 化学式: C₇H₁₁NOS
• 分子量: 157.236
• InChiKey: NNSIOAGUOSMXDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Thia-9-azabicyclo[3.3.1]nonan-7-one 、 4-氯苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 9-(4-Chlorophenyl)sulfonyl-3-thia-9-azabicyclo[3.3.1]nonan-7-one
  参考文献：
  名称：

  N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase

  摘要：

  The structural modification of a series of [3.3.1] bicyclic sulfonamide based gamma-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.060
• 作为产物：
  描述：

  9-methyl-3-thia-9-aza-bicyclo[3.3.1]nonan-7-one 在 ACE 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-Thia-9-azabicyclo[3.3.1]nonan-7-one
  参考文献：
  名称：

  N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase

  摘要：

  The structural modification of a series of [3.3.1] bicyclic sulfonamide based gamma-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.060

文献信息

• [EN] PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINES EN TANT QU'INHIBITEURS DE MTOR
  申请人：MERCK SHARP & DOHME

  公开号：WO2011090935A1

  公开（公告）日：2011-07-28

  The present invention provides Pyrazolopyrimidine Compounds of Formula (I): (I) wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

  本发明提供了式(I)的吡唑吡咯嘧啶化合物：其中L、T、Z、U、V、W、R3、R6、R7、R8和m如本文所定义，并且提供了这些吡唑吡咯嘧啶化合物的药用可接受的盐。这些吡唑吡咯嘧啶化合物在治疗癌症和其他疾病或紊乱中mTOR被破坏时是有用的。
• PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  申请人：Siddiqui M. Arshad

  公开号：US20120322791A1

  公开（公告）日：2012-12-20

  The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R 3 , R 6 , R 7 , R 8 , and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

  本发明提供了式（I）的吡唑吡咯啉化合物：其中L、T、Z、U、V、W、R3、R6、R7、R8和m如本文所定义，并且这些吡唑吡咯啉化合物的药物可接受的盐。这些吡唑吡咯啉化合物在治疗癌症和其他mTOR失调的疾病或疾病中具有用处。
• Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
  申请人：Siddiqui M. Arshad

  公开号：US09227971B2

  公开（公告）日：2016-01-05

  The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

  本发明提供了式（I）的吡唑吡咯啉化合物，其中L、T、Z、U、V、W、R3、R6、R7、R8和m的定义如本文所述，并且这些吡唑吡咯啉化合物的药学上可接受的盐。这些吡唑吡咯啉化合物可用于治疗癌症和其他mTOR失调相关的疾病或疾病。
• US9227971B2
  申请人：——

  公开号：US9227971B2

  公开（公告）日：2016-01-05
• N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase
  作者：Simeon Bowers、Gary D. Probst、Anh P. Truong、Roy K. Hom、Andrei W. Konradi、Hing L. Sham、Albert W. Garofalo、Karina Wong、Erich Goldbach、Kevin P. Quinn、John-Michael Sauer、William Wallace、Lan Nguyen、Susanna S. Hemphill、Michael P. Bova、Guriqbal S. Basi

  DOI：10.1016/j.bmcl.2009.10.060

  日期：2009.12

  The structural modification of a series of [3.3.1] bicyclic sulfonamide based gamma-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile. (C) 2009 Elsevier Ltd. All rights reserved.